Webinar - 340B: Hidden Costs and Patient Impact

Register Now

The 340B Drug Pricing Program was originally created to help safety net providers, like nonprofit hospitals and community health centers, and their patients access outpatient drugs at deeply discounted prices from manufacturers. While intended to assist the most vulnerable patients, the program has tripled over the last decade, leading to increased healthcare costs and questions about how patients are benefiting.

New research has shown that:

1. Utilization, not price increases, are driving the lion's share of this explosive growth.
    
2. Patients are not benefiting at the pharmacy counter.
    
3. There are hidden costs to states, taxpayers, patients and employers due to the increased utilization.

Join the National Pharmaceutical Council on Tuesday, July 29, from 3:00 to 4:00 PM ET for a discussion with research and patient leaders on what the program's growth means for the healthcare system, patients, and employers – and how we can course correct. 

Anna Hyde Vice President of Advocacy and Access Arthritis Foundation	Rory Martin Senior Principal, Market Access Technology Solutions IQVIA
William Sarraille Professor of Practice University of Maryland Francis King Carey School of Law	John O’Brien President & CEO NPC (moderator)